



PTO/SB/08A/B (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/509,795-Conf. #9627
				Filing Date	February 25, 2005
				First Named Inventor	Norihito OHI
				Art Unit	1626
				Examiner Name	J. M. Nolan
				Attorney Docket Number	0425-1154PUS1
Sheet	1	of	2		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY			
/JN/	BA	WO-00/35909-A1	06-22-2000			
	BB	WO-00/35921-A1	06-22-2000			
	BC	WO-00/64872-A1	11-02-2000			
	BD	WO-00/35906-A2	06-22-2000			
	BE	WO-00/75118-A1	12-14-2000			
	BF	WO-01/12609-A1	02-22-2001			
	BG	WO-01/12621-A1	02-22-2001			
	BH	WO-01/23378-A1	04-05-2001			✓
	BI	WO-01/23379-A1	04-05-2001			
	BJ	WO-01/23382-A1	04-05-2001			
	BK	EP-1 110 957-A1	06-27-2001			✓
	BL	WO-01/91749-A1	12-06-2001			✓
	BM	WO-02/10137-A2	02-07-2002			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	Kyriakis et al.; "The stress-activated protein kinase subfamily of c-Jun kinases"; Letter to Nature, vol. 369, pp 156-160, 1994	
	CB	Xia et al.; "Opposing Effects of ERK and JNK-p38 MAP Kinases on Apoptosis"; Science, vol. 270, pp. 1326-1331, 1995	
	CC	Pulverer et al.; "Phosphorylation of c-jun mediated by MAP kinases"; Letters to Nature, vol. 353, pp. 670-674, 1991	
	CD	Gupta et al.; "Selective interaction of JNK protein kinase isoforms with transcription factors"; The Embo Journal, vol. 15, no. 11, pp. 2760-2770, 1996	
	CE	Mohlt et al.; "p49 ^{3F12} Kinase: A Novel MAP Kinase Expressed in a Subset of Neurons in the Human Nervous System"; Neuron, vol. 14, pp. 67-78, 1995	
✓	CF	Kuan et al.; "The Jnk1 and Jnk2 Protein Kinases Are Required for Regional Specific Apoptosis during Early Brain Development"; Neuron, vol. 22, pp. 667-676, 1999	

Examiner Signature	/Jason Nolan/	Date Considered	03/12/2007
-----------------------	---------------	--------------------	------------

Birch, Stewart, Kolasch & Birch, LLP

MSW/RG/mao

RG



PTO/SB/08A/B (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/509,795-Conf. #9627
				Filing Date	February 25, 2005
				First Named Inventor	Norihito OHI
				Art Unit	1626
				Examiner Name	J. M. Nolan
Sheet	2	of	2	Attorney Docket Number	0425-1154PUS1

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
/JN/	CG	Sabapathy et al.; c-Jun NH ₂ -Terminal Kinase (JNK)1 and JNK2 Have Similar and Stage-dependent Roles in Regulating T Cell Apoptosis and Proliferation"; J. Exp. Med., vol. 193, no 3, pp. 317-328, 2001		
	CH	Hirosumi et al.; "A central role for JNK in obesity and insulin resistance"; Nature, vol. 420, pp. 333-336, 2002		
	CI	Yang et al.; "Absence of excitotoxicity-Induced apoptosis in the hippocampus of mice lacking the Jnk3 gene"; Letters to Nature, vol. 389, pp. 865-870, 1997		
	CJ	Ham et al.; "A c-Jun Dominant Negative Mutant Protects Sympathetic Neurons against Programmed Cell Death"; Neuron, vol. 14, pp. 927-939, 1995		
	CK	Watson et al.; "Phosphorylation of c-Jun Is Necessary for Apoptosis Induced by Survival Signal Withdrawal in Cerebellar Granule Neurons"; The Journal of Neuroscience, vol. 18, pp. 751-762, 1998		
	CL	Yuan et al.; "Apoptosis in the nervous system"; Nature, vol. 407, pp. 802-809, 2000		
	CM	Xia et al.; "Gene transfer of the JNK interacting protein-1 protects dopaminergic neurons in the MPTP model of Parkinson's disease"; PNAS, vol. 98, no. 18, pp. 10433-10438, 2001		
	CN	Savage et al.; "Activation of c-Jun N-Terminal Kinase and p38 in an Alzheimer's Disease Model is Associated with Amyloid Deposition"; The Journal of Neuroscience, vol. 22, pp. 3376-3385, 2002		
	CO	Zhu et al.; "Activation and redistribution of c-Jun N-terminal kinase/stress activated protein kinase in degenerating neurons in Alzheimer's disease"; Journal of Neurochemistry, vol. 76, pp. 435-441, 2001		
	CP	Bonni et al.; "Cell Survival Promoted by the Ras-MAPK Signaling Pathway by Transcription-Dependent and -Independent Mechanisms"; Science, vol. 286, pp. 1358-1362, 1999		
V	CQ	Han et al.; "BDNF Protects the Neonatal Brain from Hypoxic-Ischemic Injury <i>In Vivo</i> via the ERK Pathway"; The Journal of Neuroscience, vol. 20, pp. 5775-5781, 2000		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Jason Nolan/	Date Considered	03/12/2007
--------------------	---------------	-----------------	------------

Birch, Stewart, Kolasch & Birch, LLP

MSW/RG/mao

RG



- COPY -

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	Not Yet Assigned	
			Filing Date	September 29, 2004	
			First Named Inventor	Norihito OHI	
			Art Unit	N/A 1626	
			Examiner Name	Not Yet Assigned Jason Nolan	
Sheet	1	of	1	Attorney Docket Number	0425-1154PUS1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
J/N	BA**	EP-594001-A1	04-27-1994			
	BB**	EP-239191-A1	09-30-1987			
	BC**	JP-1-190681-A	07-31-1989			
	BD**	SU-1147712-A1	03-30-1985			
	BE**	WO-02/083648-A1	10-24-2002			
	BF**	WO-00/56710-A1	09-28-2000			
	BG**	WO-99/20624-A1	04-29-1999			
	BH**	WO-99/7705-A1	02-18-1999			
	BI**	WO-98/52948-A1	11-26-1998			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ** CITE NO.: Those patent(s) or publication(s) which are marked with an double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	CA**	Abdel-Aziz El-Taweel et al., Alexandria Journal of Pharmaceutical Sciences, (1998), 12(1), 11-15			
	CB**	Ghozlan, S.A.S. et al., Egyptian Journal of Pharmaceutical Sciences, (1992), 33(5-6), 859-67			
	CC**	Marei, Mohamed Gaber, Bulletin of the Chemical Society of Japan, (1993), 66(4), 1172-5			
	CD**	Rusinov, V.L. et al., Khimiya Geterotsiklichesikh Soedinenii, (1992), (11), 1560-4			
	CE**	Marei, Mohamed Gaber, Afinidad, (1993), 50(443), 55-8			
	CF**	Radinov, R. et al., Journal of Molecular Structure, (1987), 158, 99-108			
	CG**	Cecchi, L. et al., Farmaco, Edizione Scientifica, (1983), 38(1), 24-8			
	CH**	Cecchi, L. et al., Farmaco, Edizione Scientifica, (1982), 37(2), 116-22			
✓	CI**	Gastner, A. et al., Journal of Heterocyclic Chemistry, (1979), 16(6), 1141-5			
	CJ**	Kocovar, M. et al., Journal of Heterocyclic Chemistry, (1978), 15(7), 1175-84			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ** CITE NO.: Those patent(s) or publication(s) which are marked with an double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Jason Nolan/	Date Considered	03/12/2007
--------------------	---------------	-----------------	------------

RC

